

CURES WITHIN REACH RESEARCH SPOTLIGHT: PROVIDING A VOICE OF HOPE FOR CHILDREN WITH BONE CANCER

In 2021, Cures Within Reach began funding **Dr. Nancy Gordon** at **The University of Texas MD Anderson Cancer Center** to support a Phase I/II clinical trial adding hydroxychloroquine to existing chemotherapy regimens in patients with recurrent osteosarcoma. Osteosarcoma is an ultra-rare bone cancer affecting 400 children and adolescents annually in the US, with a 50%-80% rate of relapse, limited treatment options, severe side effects, and low survival outcomes.

Dr. Gordon is an expert on **osteosarcoma and pediatric oncology research**, having led several clinical trials and publications over the past two decades. She is currently the Principal Investigator of an osteosarcoma-focused research lab.

She is recognized as a leader and innovator. In 2015, she was recognized by MD Anderson with the Pediatric Clinical Innovator Award/Pediatric Multidisciplinary Award. Dr. Gordon is a Co-Investigator of a multimillion dollar grant from the Cancer Prevention and Research Institute of Texas to develop a comprehensive pediatric tumor database as a centralized repository of patient samples to improve future genetic biomarker studies. She serves as a reviewer of many journals and publications.

Dr. Gordon provides a **critical voice of hope for young patients** seeking better treatment options.



**The University of Texas
MD Anderson
Children's Cancer**

PROFILE

- Dr. Nancy Gordon has spent her career in pediatric oncology, working to create new treatments options and hope for children with bone cancer.
- Dr. Gordon studied and began her medical career in her native Venezuela before moving to Texas in 1998 and joining The University of Texas MD Anderson Cancer Center in 2001.

CWR FUNDING

- In 2021, she won CureAccelerator Live! for Pediatric Rare Diseases and support for a \$50,000 **Phase I/II clinical study** investigating the safety, feasibility, and efficacy of a new chemotherapy drug combination in patients with recurring pediatric osteosarcoma.
- Dr. Gordon and this trial represent four of CWR's communities:
 - **Rare Diseases**
 - **Oncology**
 - **Pediatrics**
 - **Diversity, Equity & Inclusion**